JP Morgan conference, Jan. 13-16 2020, San Francisco
24 December 2019
10 year anniversary and 1st patient treated with CD39 mAb
10 March 2020

Anti-CD39 immunotherapy reviewed in Medecine Sciences

A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response, published in Medecine Sciences and co-authoring Armand Bensussan, Jean-François Eliaou, Jérémy Bastid and Nathalie Bonnefoy (OREGA Biotech); Laurent Gros (INSERM); Carine Paturel and Ivan Perrot (Innate Pharma).

The review article (in French) is accessible online.